Head-to-head · free

Lycia Therapeutics Inc. vs Medtronic Plc

LYCA vs MDT — return on capital, cash generation, margins and balance sheet side by side.

LYCA

0 / 0

measures where LYCA leads

MDT

0 / 0

measures where MDT leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureLYCAMDT · FY2026
Revenue—$36.4B
Net income—$4.8B
Revenue growth (yearly, multi-year)—3.5%
Free cash flow—$5.4B
Free cash flow margin—14.9%
Net cash / (debt)——
ROIC—6.5%
Return on equity—9.8%
Gross margin—65.0%
Operating margin—18.8%
Net debt / EBITDA—2.75x

Figures are as reported by each company; latest fiscal year shown.

Where Lycia Therapeutics Inc.'s cash went

Not reported yet.

Full LYCA profile →

Where Medtronic Plc's cash went (FY2026)

Capital spending
$1.9B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MDT profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons